Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia

Recruiting Observational Study
Neoplasms Solid Tumor Breast Neoplasms Lung Neoplasms Stomach Neoplasms Uterine Cervical Neoplasms Colorectal Neoplasms Urologic Neoplasms Head and Neck Neoplasms Early Detection of Cancer Neoplasm Recurrence, Local
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
3,250 (estimated)
Sponsor
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
DNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict the cancer signal origin (CSO) from a single fluid sample, using the differential interaction between methylated and unmethylated DNA and gold nanoparticles. This prospe…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older. * Willing and able to participate and to provide the required samples (blood, urine, saliva) and demographic information (age, sex, race/ethnicity, BMI). * Able to provide written informed consent for participation and for use of biological sampl…
Contacts

Andrés Cardona, MD, MSc, PhD, MBA

+573016348173

acardona@fctic.org

CONTACT